RxCelerate Ltd has acquired Total Scientific Ltd, a contract research organisation.

The Total Scientific brand will be withdrawn and the company’s services will be provided only through RxCelerate, upon completion of the acquisition.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Based in the UK, RxCelerate is an outsourced drug development company.

The acquisition will improve RxCelerate’s position in the outsourced drug development market.

HealthCare Global Enterprises Ltd has agreed to purchase a 12% share in International Stemcell Services Ltd (ISSL) for Rs5.61m ($84,000).

HealthCare Global Enterprises will buy 10,860 equity shares from the existing shareholders of ISSL as part of the deal.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
“HealthCare Global Enterprises will buy 10,860 equity shares from the existing shareholders of ISSL as part of the deal.”

Based in India, HealthCare Global Enterprises is engaged in the provision of cancer care services.

REPROCELL Incorporated has acquired BioServe Biotechnologies (India) Private Limited from Cancer Genetics Inc for $1.9m.

REPROCELL has made an upfront payment of $1.6m in cash to Cancer Genetics as part of the transaction.

The company will pay the remaining amount based on BioServe’s revenue for a four-month period being similar to that of the same period in 2017.

Based in India, REPROCELL Incorporated is a biomedical research company, while BioServe is a DNA extraction, synthesis, sequencing and related services provider.

Raymond James & Associates Inc was appointed as the financial adviser for the transaction by Cancer Genetics.